American Journal of Public Health, Vol 90, Issue 5 699-701, Copyright © 2000 by American Public Health Association

JOURNAL ARTICLE

Helping the urban poor stay with antiretroviral HIV drug therapy

JD Bamberger, J Unick, P Klein, M Fraser, M Chesney and MH Katz
San Francisco Department of Public Health, Calif. 94102, USA. josh_bamberger@dph.sf.ca.us

Recent studies have documented dramatic decreases in opportunistic infections, hospitalizations, and mortality among HIV-infected persons, owing primarily to the advent of highly active antiretroviral medications. Unfortunately, not all segments of the population living with HIV benefit equally from treatment. In San Francisco, only about 30% of the HIV-infected urban poor take combination highly active antiretroviral medications, as compared with 88% of HIV-infected gay men. Practitioners who care for the urban poor are reluctant to prescribe these medications, fearing inadequate or inconsistent adherence to the complicated medical regimen. Persons typically must take 2 to 15 pills at a time, 2 to 3 times a day. Some of the medications require refrigeration, which may not be available to the homeless poor. Most homeless persons do not have food available to them on a consistent schedule. Therefore, they may have difficulty adhering to instructions to take medications only on an empty stomach or with food. Lack of a safe place to store medications may be an issue for some. In addition, many urban poor live with drug, alcohol, or mental health problems, which can interfere with taking medications as prescribed. Inconsistent adherence to medication regimens has serious consequences. Patients do not benefit fully from treatments, and they will become resistant to the medications in their regimen as well as to other medications in the same classes as those in their regimen. Development of resistance has implications for the broader public health, because inadvertent transmission of multidrug-resistant strains of HIV has been demonstrated. Concern that the urban poor will not adhere to highly active antiretroviral medication regimens has led to debate on the role of clinicians and public health officials in determining who can comply with these regimens. Rather than define the characteristics that would predict adherence to these regimens, the San Francisco Department of Public Health created a program to support adherence among those who may have the greatest difficulty complying with complicated highly active antiretroviral medication regimens. The program, dubbed the Action Point Adherence Project, was conceived through a community planning process in preparation for a city-wide summit on HIV/AIDS that took place in January 1998. Action Point is funded by the city and the county of San Francisco. Now in its 10th month, the program continues to show promising evidence of improving clients' biological and social indicators.

This article has been cited by other articles:

				K. Clements-Nolle, R. Marx, M. Pendo, E. Loughran, M. Estes, and M. Katz Highly Active Antiretroviral Therapy Use and HIV Transmission Risk Behaviors Among Individuals Who Are HIV Infected and Were Recently Released From Jail Am J Public Health, April 1, 2008; 98(4): 661 - 666. [Abstract] [Full Text] [PDF]

				D. P. Kidder, R. J. Wolitski, M. L. Campsmith, and G. V. Nakamura Health Status, Health Care Use, Medication Use, and Medication Adherence Among Homeless and Housed People Living With HIV/AIDS Am J Public Health, December 1, 2007; 97(12): 2238 - 2245. [Abstract] [Full Text] [PDF]

				M. Mari-Dell'Olmo, M. Rodriguez-Sanz, P. Garcia-Olalla, M I. Pasarin, M T. Brugal, J. A Cayla, and C. Borrell Individual and community-level effects in the socioeconomic inequalities of AIDS-related mortality in an urban area of southern Europe J. Epidemiol. Community Health, March 1, 2007; 61(3): 232 - 240. [Abstract] [Full Text] [PDF]

				M. B. Kushel and C. Miaskowski End-of-Life Care for Homeless Patients: "She Says She Is There to Help Me in Any Situation" JAMA, December 27, 2006; 296(24): 2959 - 2966. [Abstract] [Full Text] [PDF]

				C. Borrell, M. Rodriguez-Sanz, M. I. Pasarin, M. T. Brugal, P. Garcia-de-Olalla, M. Mari-Dell'Olmo, and J. Cayla AIDS mortality before and after the introduction of highly active antiretroviral therapy: does it vary with socioeconomic group in a country with a National Health System? Eur J Public Health, December 1, 2006; 16(6): 601 - 608. [Abstract] [Full Text] [PDF]

				P. N. Halkitis, A. H. Kutnick, and S. Slater The Social Realities of Adherence to Protease Inhibitor Regimens: Substance Use, Health Care and Psychological States J Health Psychol, July 1, 2005; 10(4): 545 - 558. [Abstract] [PDF]

				J. L. F. Antunes, E. A. Waldman, and C. Borrell Is it possible to reduce AIDS deaths without reinforcing socioeconomic inequalities in health? Int. J. Epidemiol., June 1, 2005; 34(3): 586 - 592. [Abstract] [Full Text] [PDF]

				E. Wood, J. S.G. Montaner, B. Yip, M. W. Tyndall, M. T. Schechter, M. V. O'Shaughnessy, and R. S. Hogg Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users Can. Med. Assoc. J., September 30, 2003; 169(7): 656 - 661. [Abstract] [Full Text] [PDF]

				J. A. Cook, M. H. Cohen, D. Grey, L. Kirstein, J. Burke, K. Anastos, H. Palacio, J. Richardson, T. E. Wilson, and M. Young Use of Highly Active Antiretroviral Therapy in a Cohort of HIV-Seropositive Women Am J Public Health, January 1, 2002; 92(1): 82 - 87. [Abstract] [Full Text] [PDF]

				B. R. Edlin, K. H. Seal, J. Lorvick, A. H. Kral, D. H. Ciccarone, L. D. Moore, and B. Lo Is It Justifiable to Withhold Treatment for Hepatitis C from Illicit-Drug Users? N. Engl. J. Med., July 19, 2001; 345(3): 211 - 214. [Full Text] [PDF]